NOVOMEDLINK™

This page is presented for educational purposes and is not meant to describe any Novo Nordisk products.

From Our First Patient to Our Latest Innovation
Move Left
Time Line
Move Left

Novo Nordisk is a global healthcare company with more than 87 years of innovation and achievement in diabetes care. Our commitment to research is reflected in our full portfolio of diabetes pharmaceuticals and delivery devices and the many new treatment options in our pipeline.

The story begins with Nobel-prize winning physiologist Dr. August Krogh and his belief that anyone who suffered from diabetes, including his wife Marie, should have access to insulin.

Inspired by his wife, Dr. Krogh founded Nordisk Insulinlaboratorium in 1923 and marketed the first insulin for patients. Marie was the first beneficiary—and Novo Nordisk’s first patient.

Two years later, another company - Novo Terapeutisk Laboratorium - was born, and began producing "Insulin Novo" and a unique syringe.

Over the decades, these two companies grew to be global leaders in insulin production and other areas. In January 1989, Novo and Nordisk joined forces to become the new company called Novo Nordisk.

At Novo Nordisk, our highest priority is the health and well being of patients. We are actively working to change the course of the diabetes pandemic by advancing the health care agenda to ensure patients experience quality care and treatment.

We are actively working to change the course of the diabetes pandemic, help patients living with diabetes and to expand the possibilities for people with hemophilia. Innovation and personal passsion the hallmarks of how we operate.

To learn more please visit the Novo Nordisk website.

Novo Nordisk is Committed to Diabetes
Changing how we care for diabetes

We are dedicated to diabetes - how it is treated, how it is viewed around the world, and how the future of this disease plays out.

At Novo Nordisk we are fighting the diabetes pandemic in many ways, and the resources we dedicate to diabetes research are unparalleled in the industry

Changing how we work in diabetes

Novo Nordisk was one of the first companies to introduce insulin to the world, and since then we have helped to change how diabetes is treated. Today, Novo Nordisk devotes more resources to diabetes research than any other company, second only to the U.S. government.

For those with diabetes who have difficulty affording their medication, Novo Nordisk's Diabetes Patient Assistance Program(PAP) provides products to those who financially qualify. For more information about the Novo Nordisk Diabetes PAP click here.

Changing the global agenda in diabetes

As a world leader in diabetes care, we have the potential and responsibility to make a difference for people with diabetes, facilitating change in addition to providing treatments.

World Diabetes Foundation (WDF):

Novo Nordisk launched WDF to support the prevention and treatment of diabetes where it is most needed.

  • Impacted 75 million people worldwide
  • Supported 253 projects in 96 countries
Diabetes in Children:

Novo Nordisk works in cooperation with local partners, governments and diabetes associations in some of the world’s poorest countries to build sustainable national capacity for diabetes treatment and establish clinics for children with type 1 diabetes

Diabetes Barometer:

The Barometer is the first comprehensive national benchmark against which we can measure the public’s understanding of diabetes, its economic impact, and gaps in diabetes measurement. The Diabetes Barometer will enable you, as a health care provider, to benchmark your practices against your colleagues.

Changing the course of diabetes

Our approach has always been rooted in the philosophy that the patient should be at the center of care. We have created programs to provide educational resources to patients and health care providers.

Ask.Screen.Know: is a program that raises awareness about the importance of diabetes screening. Click here for useful diabetes tools for your patients.

Novo Nordisk is a long-time supporter of diabetes camp for children nationwide, providing programs and activities that are fun and educational. Programs include:

  • "Camp in a Kit" with camp essential

  • “I Can Do More” camp program providing educational tools, fundraising events and product donations

Picture This: Diabetes, a project in partnership with the Entertainment Industries Council (EIC), works to engage diverse diabetes stakeholders, the entertainment creative community and news media in reaching a consensus about diabetes communications challenges and ways to strengthen understanding about the disease through media on a national and local level.

  • ThePicture This: Diabetes national forum was held in Washington, D.C. The national forum participants identified comunication challenges and explored strategies to strengthen accurate storytelling through entertainment and news media. For more information visit www.eiconline.org/diabetes

  • Locally, participants work to identify communication challenges and explore strategies to strengthen community understanding about diabetes through news media and community affairs programs. Learn more through WPVI-TV(Philadelphia) and KING-5-TV (Seattle); additional local programs are planned for Atlanta, GA, Chicago, IL and Los Angeles, CA

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

This link will take you to a website outside of Novo
Nordisk’s network, are you sure you want to
proceed?

Triple Bottom Line: Responsible Business is Healthy Business

Novo Nordisk is driven by our Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success.

Our Triple Bottom Line Approach

As we see it, a business can only be sustainable in the long term if it meets expectations regarding social and environmental impact, in addition to delivering on corporate objectives. This is the core of our Triple Bottom Line approach.

Financial responsibilty
Financial responsibilty

Being financially responsible is about managing the business in a way that secures growth and prosperity. This includes delivering solid financial results for shareholders and contributing to socio-economic welfare. The way money is earned is equally important. Ethical business conduct, transparent and responsible business practices lie at the heart of financial responsibility.

Social responsibility
Social responsibility

Being socially responsible is about caring for people. This applies to the people who depend on our products as well as to our employers. Driven by our commitment to diabetes we invest in finding better methods of detecting and treating the disease. We work to raise awareness, drive health outcomes and improve access to diabetes care around the world. To remain an attractive workplace, Novo Nordisk invests in people development and health and safety, and promotes a culture of diversity.

Environmental responsibility
Environmental responsibility

Being environmentally responsible is about minimizing negative impacts generated by our production and the use of our products. Environmental responsibilty is also about sustainable development in a broader sense. In addition to reducing negative impacts, our approach focuses on actively contributing to solving global challenges such as climate change and resource scarcity.

  • From Our First Patient to Our Latest Innovation

  • Novo Nordisk is Committed to Diabetes

  • Triple Bottom Line: Responsible Business is Healthy Business